MedTrace Logo

Prevention of Decompensation in Liver Cirrhosis

NCT00239096 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2005-10-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.

Conditions

  • Alcoholic Liver Cirrhosis
  • Ascites

Interventions

DRUG

losartan (drug)

Sponsors & Collaborators

  • Lundbeck Foundation

    collaborator OTHER

  • University of Southern Denmark

    collaborator OTHER

  • Else Poulsen Mindelegat

    collaborator UNKNOWN

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Annette Dam, MD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2011-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239096 on ClinicalTrials.gov